COMPASS Pathways plc (NASDAQ:CMPS) Given Consensus Recommendation of “Buy” by Brokerages

COMPASS Pathways plc (NASDAQ:CMPS) has been given an average rating of “Buy” by the six analysts that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last year is $47.40.

Several equities research analysts have weighed in on CMPS shares. Canaccord Genuity Group lowered their target price on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a research note on Friday, August 23rd. Royal Bank of Canada restated an “outperform” rating and set a $23.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, September 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock opened at $6.21 on Friday. The stock’s fifty day moving average is $7.02 and its two-hundred day moving average is $7.51. The company has a market capitalization of $424.65 million, a PE ratio of -2.62 and a beta of 2.26. The company has a quick ratio of 12.03, a current ratio of 12.03 and a debt-to-equity ratio of 0.13. COMPASS Pathways has a 52 week low of $5.01 and a 52 week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same quarter in the prior year, the company earned ($0.62) earnings per share. As a group, analysts expect that COMPASS Pathways will post -2.35 earnings per share for the current year.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the sale, the insider now directly owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.25% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Logos Global Management LP increased its holdings in shares of COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after purchasing an additional 901,050 shares during the period. Renaissance Technologies LLC increased its holdings in shares of COMPASS Pathways by 1,518.4% in the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after purchasing an additional 247,500 shares during the period. Fore Capital LLC acquired a new position in shares of COMPASS Pathways in the second quarter valued at about $181,000. AdvisorShares Investments LLC increased its holdings in shares of COMPASS Pathways by 13.5% in the second quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock valued at $362,000 after purchasing an additional 7,243 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of COMPASS Pathways in the second quarter valued at about $664,000. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.